Analytical Data
-
Gene name
CTGF
- Application
-
Alternative Names
CTGF；CTGF；HCS24；IGFBP8；CCN family member 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P29279
-
Expression Region
253-349aa
-
AA Sequence
MGKKCIRTPK ISKPIKFELS GCTSMKTYRA KFCGVCTDGR CCTPHRTTTL PVEFKCPDGE VMKKNMMFIK TCACHYNCPG DNDIFESLYY RKMYGDMA
-
Molecular Weight
11 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Connective Tissue Growth Factor (CTGF), also known as CCN2, is a multifunctional protein that plays a crucial role in various biological processes, including cell proliferation, differentiation, and extracellular matrix formation. It is particularly significant in fibrotic diseases, wound healing, and tissue remodeling, making it a key target in therapeutic research. Elevated levels of CTGF are often associated with pathological conditions such as pulmonary fibrosis, diabetic nephropathy, and systemic sclerosis, highlighting its potential as a biomarker and therapeutic target. The recombinant CTGF protein has been extensively studied to understand its mechanisms of action and therapeutic potential. By producing and purifying CTGF in laboratory settings, researchers can investigate its effects on cell signaling pathways and tissue interactions. Furthermore, recombinant CTGF enables the development of engineered therapeutic strategies aimed at modulating its activity to either promote healing in fibrotic conditions or inhibit its effects in instances of excessive fibrosis. The ongoing research into CTGF not only enhances our understanding of its biological functions but also provides valuable insights for devising novel treatments for fibrotic diseases and improving tissue regeneration strategies.
